Fundraising Fox
Oblenio Bio
Lexington, US · 10 employees on LinkedIn · 2 known investors
Find your way into Oblenio Bio
Sign up to see every warm intro you have to Oblenio Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oblenio Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
Founders & leadership
ST
Samantha TruexCEO of Oblenio BioShe previously served as CEO of Upstream Bio and of Quench Bio, and earlier held operating roles as COO and Head of Corporate Development at Synlogic Therapeutics and Chief Business Officer at Padlock Therapeutics. She chairs the board of Artios and sits on the board of Avalo Therapeutics, where she chairs the nominating and governance committee, following earlier board service at HotSpot Therapeutics.
Investors · 2
Funding
SEC filings, press & company announcements$62M disclosed across 1 round · 2026
- $62MSeries BJun 2026 · 7 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 8
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
iBioiBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
bioioBIOIO develops a genetics-based platform for elucidating drug mechanisms of action, combining decades of research in pharmacology with big data and automation to accelerate drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to understand how drugs work.
Primrose BioPrimrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
IndieBioIndieBio was a startup accelerator and pre-seed investment program launched by SOSV in San Francisco in 2015, providing on-site bio-labs and funding to science founders across biotech, food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics. As of 2026 the program was rebranded to SOSV NY and SOSV SF, expanding its focus from bio to broader deep tech.
Sanegene BioSanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.
Companies working in the same space as Oblenio Bio.
In the news
Frequently asked questions
- What does Oblenio Bio do?
- Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
- Who are Oblenio Bio's investors?
- Oblenio Bio's investors include Aditum Bio, GV (Google Ventures).
- How much funding has Oblenio Bio raised?
- Oblenio Bio has disclosed $62M raised across 1 round.
- Where is Oblenio Bio headquartered?
- Oblenio Bio is headquartered in Lexington, US.